Back Hepatitis C

Hepatitis C

AASLD 2016: 6 Weeks of Sofosbuvir/Ledipasvir Cures Genotype 1 Acute Hepatitis C

A short course of sofosbuvir/ledipasvir (Harvoni) taken for 6 weeks cured 100% of HIV-negative people with genotype 1 acute hepatitis C virus (HCV) infection, including those with high viral loads, according to study results presented at the 2016 AASLD Liver Meeting this month in Boston.

alt

AASLD 2016: Non-Adherence Is Most Important Risk Factor for Sofosbuvir/Ledipasvir Failure

Research carried out by researchers at Mount Sinai Medical Center in New York found that non-adherence was the strongest risk factor for treatment failure in people taking sofosbuvir/ledipasvir (Harvoni) to treat hepatitis C. The main reasons cited for non-adherence were failing to take medication as prescribed and hospitalization, according to a report at the 2016 AASLD Liver Meeting in Boston earlier this month.

alt

AASLD 2016: Primary Care Providers Can Effectively Treat Patients with Hepatitis C

Primary care providers such as non-specialist physicians and nurse practitioners can be quickly trained to provide direct-acting antiviral (DAA) therapy for hepatitis C with a high level of treatment success and provider satisfaction, according to a presentation at the 2016 AASLD Liver Meeting this month in Boston.

alt

AASLD 2016: Portal Hypertension Less Likely to Improve After HCV Treatment When Fibrosis Is Severe

Curing hepatitis C infection moderately reduces portal hypertension, but has less impact for people with more severe liver stiffness due to fibrosis, Spanish researchers reported at the 2016 AASLD Liver Meeting this month in Boston.

alt

AASLD 2016: U.S. Veterans Health System and Australia Show Potential for Rapid Hepatitis C Elimination

If sufficient money is available to pay for direct-acting antivirals (DAAs), the U.S. Veterans Health Administration could cure hepatitis C in the majority of veterans under its care within 3 years, and has already shown it has the capacity to start almost 7000 people on treatment in a single month, George Ioannou of the University of Washington in Seattle reported at the AASLD Liver Meeting last week in Boston.

alt

AASLD 2016: Hepatitis C Virus Infections Rising Among HIV+ Gay Men in San Diego

The prevalence of hepatitis C virus (HCV) infection among HIV-positive men who have sex with men in San Diego has increased over the past 15 years, especially among men who do not inject drugs but use methamphetamine, according to a study presented at the 2016 AASLD Liver Meeting this month in Boston. Another study by the same research team found that post-treatment reinfection is also a concern in this population.

alt

AASLD 2016: Grazoprevir Triple Regimen Demonstrates High Cure Rates, Even for Hard-to-Treat Patients

A new 3-drug coformulation containing Merck's grazoprevir plus the investigational agents MK-3682 and ruzasvir was highly effective for people with hepatitis C virus (HCV) genotypes 1, 2, or 3, with sustained response rates of 86% to 100% depending on treatment duration, according to study results presented this month at the AASLD Liver Meeting in Boston. Related studies showed that the combination is also effective for retreating people who were not cured with a previous course of direct-acting antivirals (DAAs).

alt

AASLD 2016: Birth Cohort Screening and Linkage to Hepatitis C Care Still Weak in U.S.

Grave weaknesses in hepatitis C virus (HCV) screening and linkage to care are still widespread in the United States and threaten to leave a large proportion of Baby Boomers with hepatitis C untreated, according to presentations at the 2016 AASLD Liver Meeting this month in Boston.

alt

AASLD 2016: 8-Week Triple Combo Cures Most Patients with Genotype 1-6 Hepatitis C

A 3-drug regimen of sofosbuvir, velpatasvir, and voxilaprevir taken for 8 weeks demonstrated an overall sustained virological response rate of 95% for previously untreated patients with all hepatitis C virus (HCV) genotypes, while a 12-week regimen cured 96%-97% of people who experienced prior treatment failure on direct-acting antivirals (DAAs), according to a set of Phase 3 studies presented last week at the AASLD Liver Meeting in Boston.

alt